Risk factors

Kura Oncology (KURA) risk factors

Item 1A of every Kura Oncology, Inc. 10-K on file, and what changed from one year to the next.

Open KURA in Gloomberb →
  • FY2025 10-K risk factors

    85 risks, 20 new, 17 dropped, 28 reworded since the prior year. Transitioning from clinical stage to commercial stage following the approval of KOMZIFTI for NPM1-mutated AML in November 2025. Facing new execution, regulatory compliance, co-promotion, and commercialization risks.

    Filed Mar 05, 2026
  • FY2024 10-K risk factors

    82 risks. Kura Oncology faces heavy clinical, regulatory, and financial risks as a pre-revenue biopharmaceutical company with no approved products.

    Filed Feb 28, 2025